Toll-like receptor modulators: a patent review (2006 – 2010) (Q37853197)

24 August 2017

1 reference

reason for preferred rank

title

Toll-like receptor modulators: a patent review (2006 – 2010) (English)

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

Toll-like receptor modulators: a patent review (2006-2010) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21406035

27 November 2024

0 references

Shaherin Basith

1

1 reference

24 August 2017

Balachandran Manavalan

2

1 reference

24 August 2017

Gwang Lee

3

1 reference

24 August 2017

Sang Geon Kim

4

1 reference

24 August 2017

Sangdun Choi

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

full work available at URL

24 August 2017

http://www.informapharmascience.com/doi/abs/10.1517/13543776.2011.569494

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21406035

http://www.tandfonline.com/doi/pdf/10.1517/13543776.2011.569494

27 November 2024

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Expert Opinion on Therapeutic Patents

27 November 2024

published in

1 reference

24 August 2017

volume

21

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

927-944

1 reference

The innate signaling of dangers and the dangers of innate signaling

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A family of human receptors structurally related to Drosophila Toll

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The evolution of vertebrate Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Genomic insights into the immune system of the sea urchin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The Toll-IL-1 receptor adaptor family grows to five members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptors in systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Targeting Toll-like receptors: emerging therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Characterization of bovine Toll-like receptor 8: ligand specificity, signaling essential sites and dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Immunobiology of Toll-like receptors: emerging trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Drugs targeting Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Synthetic agonists of Toll-like receptors 7, 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Functional diversification of the toll-like receptor gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Innate immune sensing and activation of cell surface Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Recent advances with TLR2-targeting lipopeptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Self-adjuvanting lipopeptide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Role of neutrophils in BCG immunotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

TLR3 can directly trigger apoptosis in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Crystal structure of human toll-like receptor 3 (TLR3) ectodomain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4 T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Dendritic cells require a systemic type I interferon response to mature and induce CD4 Th1 immunity with poly IC as adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Case-control study of human papillomavirus and oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptors and immune regulation: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

TLR7 and TLR8 as targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Primary leukocyte screens for innate immune agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Vaccine adjuvants: scientific challenges and strategic initiatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Strategies for targeting T-cells in allergic diseases and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Emerging drugs for the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Modulation of atherosclerosis in mice by Toll-like receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Activation of mammalian Toll-like receptors by endogenous agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Therapeutic targeting of pattern-recognition receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Targeting toll-like receptors for drug development: a summary of commercial approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Systemic lupus erythematosus: all roads lead to type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Molecular Modeling-Based Evaluation of hTLR10 and Identification of Potential Ligands in Toll-Like Receptor Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Structure-Function Relationship of Cytoplasmic and Nuclear IκB Proteins: An In Silico Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Harmful molecular mechanisms in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Application of beta-lactamase enzyme complementation to the high-throughput screening of toll-like receptor signaling inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

21 January 2018

44

11

133

Panter G

2009

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8 T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

27 November 2024

48

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Mammalian Toll-like receptors

27 November 2024

52

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

Toll-free vaccines?

54

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

27 November 2024

60

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

27 November 2024

62

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans

27 November 2024

68

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Flavor Decomposition of the Sea-Quark Helicity Distributions in the Nucleon from Semiinclusive Deep Inelastic Scattering

27 November 2024

75

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

82

10

10

Dorn A

2008

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial

27 November 2024

98

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms

27 November 2024

106

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus

27 November 2024

107

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

108

10

21

Parkinson T

2008

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

Annals of the Rheumatic Diseases

27 November 2024

111

67

iii50

Sheedy FJ

2008

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

113

6

166

Ishii KJ

2004

1 reference

https://api.crossref.org/works/10.1517/13543776.2011.569494

27 November 2024

Identifiers

1 reference

24 August 2017

1 reference